KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin (2018 - 2026)

Aurinia Pharmaceuticals filings provide 8 years of EBIT Margin readings, the most recent being 43.1% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 4589.0% to 43.1% in Q4 2025 year-over-year; TTM through Dec 2025 was 37.06%, a 3906.0% increase, with the full-year FY2025 number at 37.06%, up 3906.0% from a year prior.
  • EBIT Margin hit 43.1% in Q4 2025 for Aurinia Pharmaceuticals, up from 40.49% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 43.1% in Q4 2025 to a low of 5529.87% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 34.4% (2023), compared with a mean of 361.57%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 14557048bps in 2021 and later tumbled -1280bps in 2023.
  • Aurinia Pharmaceuticals' EBIT Margin stood at 139.74% in 2021, then increased by 29bps to 98.82% in 2022, then skyrocketed by 33bps to 65.8% in 2023, then skyrocketed by 96bps to 2.79% in 2024, then surged by 1646bps to 43.1% in 2025.
  • The last three reported values for EBIT Margin were 43.1% (Q4 2025), 40.49% (Q3 2025), and 28.69% (Q2 2025) per Business Quant data.